Dr Romain Appay, pathologist at the Timone Hospital and PhD student in the GioME team, has published a new research paper entitled "Rosette-forming glioneuronal tumours are midline, FGFR1- mutated tumours" in the Neuropathology and Applied Neurobiology journal.
The Aim of the study: Rosette-forming glioneuronal tumour (RGNT) is a rare central nervous system (CNS) World Health Organization (WHO) grade 1 brain neoplasm. According to the WHO 2021, essential diagnostic criteria are a ‘biphasic histomorphology with neurocytic and a glial component, and uniform neurocytes forming rosettes and/or perivascular pseudorosettes associated with synaptophysin expression’ and/or DNA methylation profile of RGNT whereas ‘FGFR1 mutation with co-occurring PIK3CA and/or NF1 mutation’ are desirable criteria.
A second article has been published in Journal of neurological sciences entitled: Genomic analysis of paired IDHwt glioblastomas reveals recurrent alterations of MPDZ at relapse after radiotherapy and chemotherapy.
The authors aimed to identify genomic drivers of glioblastoma inevitable recurrence.Their results suggest that MPDZ is more frequently altered at relapse after radio-chemotherapy in glioblastoma IDHwt patients, suggesting that MPDZ impairment could contribute to the systematic resistance of these tumors opening new therapeutic perspectives.